The drug by Teva was approved in China in 2018, and is the first original product marketed by Teva for the treatment of inert B-cell non-Hodgkin's lymphoma.

Teva的药物于2018年在中国获批，是Teva销售的第一款用于治疗惰性B细胞非霍奇金淋巴瘤的原创产品。

The inorganic components can be turned into inert slag," Zhao said.

"The approval of this product indicates a significant step forward in the development of additive manufacturing for medical devices, from single materials to composite materials, and from biologically inert materials to biologically active materials," said Wu Suhua, general manager of Wedo-Bio.